GenFleet Therapeutics is a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, founded in 2017 by veteran drug developers with the support from top-tier venture capital investors. Dedicated to serving significant unmet medical needs, GenFleet Therapeutics established its proprietary R&D platform based on the deep understanding of disease biology, translational medicine, as well as the research into latest biological mechanism of cancer pathways, tumor microenvironment and human immunoregulation. GenFleet's rich and diversified pipeline highlights multiple cutting-edge products with novel mechanisms and global IP.
Staff with Master or Doctoral Degrees
Since its inception in 2017, GenFleet has built up industry-leading capabilities and expertise in developing novel drug candidates - both small molecules and biologics. Its pipeline includes over 10 programs in development, many of which have entered clinical stages.
Among them, the TGF-β R1 (transforming growth factor-β receptor 1) inhibitor has entered phase Ib/II clinical trial and boasts broad prospects of treating solid tumors with lower response rates to PD-1 inhibitors; the CDK9（cyclin-dependent kinase 9） inhibitor has been granted with IND approval in China and US, marking the beginning of the company's global multi-center clinical trial strategy；besides, GenFleet is the first Chinese company that moves RIPK1 inhibitor development into clinical stage. In mid 2021, GenFleet also received IND approval to proceed with the clinical trials of its KRAS G12C inhibitor.
Bringing in over two decades of experiences in the pharmaceutical industry, Dr. Li was involved in numerous programs of approved drugs and diagnostics. His expertise ranges from process development, quality control validation, scale-up manufacturing to other core technologies related with the upstream & downstream sectors of the industry and led various teams to develop preclinical and clinical batches of different monoclonal antibodies, therapeutic vaccines and recombinant protein products.
This round of financing is led by Huagai Capital, with participation by new investors including Suxin Venture Capital, Cherami Investment Group, ABC International, DYEE Capital, Qiaojing Eastern Investment, Baidu Venture, and Wenzhou Capital. Existing investors including CDH Venture and Growth Capital, Lake Bleu Capital, HM Capita, Panlin Capital, Shanjin Asset also participated. Start Point Advisors act as the sole financial advisor.
This multi-center trial the first POC (proof of concept) study designed by GenFleet and it's also the company's third program involving global research sites. GFH018 demonstrated excellent safety profile in phase I trial. Preclinical data also suggested antitumor effects of low-dose GFH018 in combination with PD-1 inhibitors.